At the start of the New Year, Dr Carl June (@carlhjune) who needs no introduction as one of pioneers of Chimeric Antigen Receptor (CAR) T cell therapy tweeted that, “2020 will be the decade of cell therapy and genome engineering.”

So what does the next decade hold for CAR T cell therapy?

At the recent 2nd European CAR T cell meeting, jointly organized by EHA and EBMT, we asked the man himself to tell us more about his vision.

In Sitges, Dr June kindly spoke to BSB and shared his thoughts on where he sees the CAR T field going, some of the key challenges that will need to be overcome, as well as some of the opportunities to watch out for.

To learn more from our oncology coverage and get a heads up on our latest analysis, commentary, and a global expert interview from a CAR T cell therapy specialist, subscribers can log-in or you can click to gain access to BSB Premium Content.

This content is restricted to subscribers

Posted by